ATS 2019 Virtual Final Program

CLINICAL • TRANSLATIONAL THEMATIC POSTER SESSION A31 ASTHMA: CLINICAL STUDIES I 9:15 a.m. - 4:15 p.m. KBHCCD Area E (Hall F, Level 2) Viewing: Posters will be on display for entire session. Discussion: 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators. Facilitator : P. Akuthota, MD, La Jolla, CA P655 Dupilumab in Severe Asthma: A Real-Life Cohort in France/ C. Dupin, L. Guilleminault, P. Bonniaud, A.-S. Gamez, C. Leroyer, G. Mahay, F. De Blay, S. Fry, G. Le Bourdellès, A. Proust, L. Rosencher, D. Belhadi, P. Berger, A. Dider, A. Bourdin, C. Chenivesse, G. Garcia, C. Couffignal, C. Taillé, Paris, France, p.A1267 P656 Effect of Pre-Seasonal Use of Omalizumab on Fall Asthma Exacerbations in School-Age Children Using a US Claims Database/ N.A. Hanania, J. Fang, B. Ortiz, L. Alvares, X. Jaumont, A. Kavati, H. Tian, H. Cao, Houston, TX, p.A1268 P657 Oral Corticosteroids Use Patterns in Asthma GINA Steps 4 and 5 Patients in a US Commercially Insured Population/ N.A. Hanania, J. Fang, P. Altman, B. Ortiz, L. Alvares, L. Zhou, H. Cao, Houston, TX, p.A1269 P658 Effect of Reversibility and Eosinophils on Lung Function Improvement with Omalizumab Treatment: Pooled Analyses in Patients with Moderate or Severe Allergic Asthma/ T.B. Casale, B.E. Chipps, T. Haselkorn, A. Iqbal, B. Yoo, B. Ortiz, B.Q. Lanier, N.A. Hanania, Tampa, FL, p.A1270 P659 Response Rate Improvement and Systemic Corticosteroid Burden Reduction with Intravenous (IV) Reslizumab in a Subgroup of Asthma Patients with GINA 4/5 Severity and >=2 Clinical Asthma Exacerbations (CAEs) in the Prior 12 Months/ M. Wechsler, L. Hickey, M.C. Garin, A. Chauhan, Denver, CO, p.A1271 P660 Assessment of Response to Anti-IL-5 Monoclonal Antibodies in a Tertiary Care Centre: A Real-Life Study/ S. Tran, J. L’Archeveque, I. Coman, A. Cartier, C. Lemiere, Montreal, Canada, p.A1272 P661 Real-World Effectiveness of Mepolizumab in an Academic Asthma Clinic/ P. Sharma, C.A. Vitari, M. Tuft, S.E. Wenzel, Pittsburgh, PA, p.A1273 P662 Efficacy of Mepolizumab in Patients with Severe Eosinophilic Asthma by Age of Asthma Onset: Meta-Analysis of Two Phase III Trials/ F.C. Albers, N.A. Hanania, M. Kraft, D.J. Bratton, E. Bradford, S.G. Smith, C.M. Prazma, G. Brusselle, Research Triangle Park, NC, p.A1274 P663 Type 2 Biomarkers and Eosinophil Activation in Severe Asthma and the Impact of Mepolizumab/ P. Howarth, S. Quirce, A. Papi, E. Israel, S. Mallett, S. Bates, F.C. Albers, N. Kwon, Brentford, United Kingdom, p.A1275 P664 The Effectiveness of Combination Therapy of Severe Asthma by Tiotropium with ICS/LABA in Patients with Cold Airway Hyperresponsiveness/ J.M. Perelman, A.B. Pirogov, A.G. Prikhodko, D.A. Gassan, Blagoveshchensk, Russian Federation, p.A1276 P665 The Efficacy of the Combination Indacaterol/Glycopyrronium/ Mometasone Furoate Is Independent of Time of Dosing in Patients with Asthma/ J. Beier, H. Watz, V. Scholz, Z. Diamant, J.M. Hohlfeld, D. Singh, P. Pinot, K. Lheritier, A. Sarkar, H.C. Tillmann, Wiesbaden, Germany, p.A1277 P666 A Cumulative Dose (1440 µg) Study to Evaluate the Efficacy, PK, Extrapulmonary PD, and Safety of Albuterol Sulfate MDI in Co-Suspension Delivery Technology (AS MDI; PT007) in Patients with Asthma/ A. Maes, C. Cappelletti, K. Rossman, M. Gillen, C.F. LaForce, C. Reisner, Morristown, NJ, p.A1278 P667 Health Related, Cross-Sectional, Case Control, Drug Utilization Surveillance Study on Home Nebulization in Bronchial Asthma (H R A A Study)/ D. Talwar, S. Bendre, K. Korukonda, Noida, India, p.A1279 Facilitator : J.K. Kolls, MD, New Orleans, LA P668 Impaired Glucose Metabolism Is Associated with Asthma Severity in the Severe Asthma Research Program-3 (SARP-3) Cohort/ M.C. Peters, M. Schiebler, E.R. Bleecker, M. Castro, S.C. Erzurum, A.T. Hastie, B.D. Levy, J.C. Cardet, E. Israel, B. Phillips, D. Mauger, M.W. Johansson, S.E. Wenzel, N.N. Jarjour, J.V. Fahy, San Francisco, CA, p.A1280 P669 Ceramide as a Key Player in Obesity Exacerbated Asthma/ J.L. Sturgill, M. Khosravi, J. Allegood, S. Spiegel, Lexington, KY, p.A1281 P670 Gastroesophageal Reflux Predicts Asthma Exacerbations in Obese Asthmatics/ A. Ghincea, D. Chhabra, A. Shah, F. Chung, E.R. Bleecker, A.M. Fitzpatrick, M. Castro, S.E. Wenzel, B.M. Gaston, E. Israel, W.G. Teague, W.C. Moore, S.P. Peters, N.N. Jarjour, S.C. Erzurum, F. Holguin, S. Sharma, Aurora, CO, p.A1282 P671 Association of sIL1RA Levels with Lung Function in Asthma and Divergence with World Trade Center Related Lower Respiratory Symptoms/ N. Durmus, Y. Zhang, K. Doo, G. Grunig, M. Cotrina-Vidal, Y. Shao, J. Reibman, New York, NY, p.A1283 P672 Evaluation of Blood Eosinophil Measurements Between Local and Central Laboratories/ M. Bafadhel, C. Holweg, A. Iqbal, A. Chai, B. Yoo, N.N. Jarjour, Oxford, United Kingdom, p.A1284 P673 L-Arginine Intervention in Severe Asthma Patients/ S.Y. Liao, A. Linderholm, C. Kivler, L. Franzi, M. Showalter, Y. Li, L. Qi, O. Fiehn, A.A. Zeki, N.J. Kenyon, Sacramento, CA, p.A1285 P674 Characterization of Asthma-COPD Overlap in an Asthma Cohort/ Z. Lipkin-Moore, J. Gomez, G. Chupp, New Haven, CT, p.A1286 P675 Impact of Intrinsic and Extrinsic Factors on the Variability of Blood Eosinophil Levels in Asthma/ J. Corren, W.J. Calhoun, C.T.J. Holweg, A. Iqbal, B. Yoo, J. Brumm, C. Chung, B.E. Chipps, Los Angeles, CA, p.A1287 ATS 2019 • Dallas, TX SUNDAY • MAY 19 45 SUNDAY MORNING